Viatris (VTRS) ROE: History & Chart

Viatris Inc.(VTRS)

Drug Manufacturers - Specialty & Generic · Canonsburg, PA

$16.95-0.18 (-1.05%)

Delayed quote: Sep 18, 2026, 4:00 PM EDT

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Canonsburg, PA

30,000 employees

www.viatris.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Scott Andrew Smith

View full financials

VTRS Return on Equity (ROE) Metrics

RETURN ON EQUITY (ROE)

-2.88%

RETURN ON EQUITY (ROE) AVG TTM

-15.07%

RETURN ON EQUITY (ROE) AVG 3Y

-7.16%

RETURN ON EQUITY (ROE) AVG 5Y

-4.29%

RETURN ON EQUITY (ROE) AVG 10Y

1.28%

RETURN ON EQUITY (ROE) AVG 15Y

N/A

RETURN ON EQUITY (ROE) AVG 20Y

N/A

CURRENT VS TTM AVG

+80.88%

CURRENT VS 3Y AVG

+59.77%

CURRENT VS 5Y AVG

+32.93%

CURRENT VS 10Y AVG

-325.86%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

13.01%

median of 84 covered companies

CURRENT VS SECTOR MEDIAN

-122.14%

vs the sector median at left

NAME	MARKET CAP	RETURN ON EQUITY (ROE)	TTM	3Y	5Y
Viatris Inc. (VTRS)	$19.74B	-2.88%	-15.07%	-7.16%	-4.29%
STERIS plc (STE)vs ›	$19.98B	11.17%	10.12%	7.00%	7.00%
United Therapeutics Corporation (UTHR)vs ›	$21.00B	20.48%	18.68%	17.25%	16.03%
Zimmer Biomet Holdings, Inc. (ZBH)vs ›	$18.45B	6.39%	6.40%	5.73%	4.16%
Medpace Holdings, Inc. (MEDP)vs ›	$17.09B	113.29%	73.63%	65.34%	49.74%
Revvity, Inc. (RVTY)vs ›	$16.00B	3.29%	3.59%	3.35%	7.68%
Solventum Corporation (SOLV)vs ›	$15.38B	29.88%	23.51%	17.50%	13.68%
BioNTech SE (BNTX)vs ›	$24.13B	-9.62%	-4.55%	10.63%	21.70%
Exelixis, Inc. (EXEL)vs ›	$14.67B	46.68%	29.72%	22.87%	17.28%
Incyte Corporation (INCY)vs ›	$25.40B	25.41%	12.92%	11.29%	9.83%

NAME

MARKET CAP

RETURN ON EQUITY (ROE)

TTM

Viatris Inc. (VTRS)

$19.74B

-2.88%

-15.07%

-7.16%

-4.29%

STERIS plc (STE)vs ›

$19.98B

11.17%

10.12%

7.00%

United Therapeutics Corporation (UTHR)vs ›

$21.00B

20.48%

18.68%

17.25%

16.03%

Zimmer Biomet Holdings, Inc. (ZBH)vs ›

$18.45B

6.39%

6.40%

5.73%

4.16%

Medpace Holdings, Inc. (MEDP)vs ›

$17.09B

113.29%

73.63%

65.34%

49.74%

Revvity, Inc. (RVTY)vs ›

$16.00B

3.29%

3.59%

3.35%

7.68%

Solventum Corporation (SOLV)vs ›

$15.38B

29.88%

23.51%

17.50%

13.68%

BioNTech SE (BNTX)vs ›

$24.13B

-9.62%

-4.55%

10.63%

21.70%

Exelixis, Inc. (EXEL)vs ›

$14.67B

46.68%

29.72%

22.87%

17.28%

Incyte Corporation (INCY)vs ›

$25.40B

25.41%

12.92%

11.29%

9.83%

Return on Equity (ROE) FAQ

What is the return on equity (ROE) for Viatris Inc. (VTRS)?

The return on equity (ROE) for VTRS stock is -2.88%.

Is Viatris Inc.'s return on equity (ROE) high or low?

The return on equity (ROE) of -2.88% is 33% above its 5-year average of -4.29%, around the middle of its 5-year range (-24.26%–9.86%).

What is the TTM average return on equity (ROE) for Viatris Inc. (VTRS)?

The TTM average return on equity (ROE) for VTRS stock is -15.07%.

What is the 3Y average return on equity (ROE) for Viatris Inc. (VTRS)?

The 3Y average return on equity (ROE) for VTRS stock is -7.16%.

What is the 5Y average return on equity (ROE) for Viatris Inc. (VTRS)?

The 5Y average return on equity (ROE) for VTRS stock is -4.29%.

What is the 10Y average return on equity (ROE) for Viatris Inc. (VTRS)?

The 10Y average return on equity (ROE) for VTRS stock is 1.28%.

DATE	RETURN ON EQUITY (ROE)
2026-06-30	-2.88%
2026-03-31	-2.02%
2025-12-31	-23.89%
2025-09-30	-24.26%
2025-06-30	-22.27%
2025-03-31	-24.22%
2024-12-31	-3.40%
2024-09-30	-4.46%
2024-06-30	-3.31%
2024-03-31	-0.28%
2023-12-31	0.27%
2023-09-30	8.78%
2023-06-30	8.90%
2023-03-31	9.10%
2022-12-31	9.86%
2022-09-30	4.19%
2022-06-30	3.84%
2022-03-31	0.82%
2021-12-31	-6.19%
2021-09-30	-9.09%
2021-06-30	-9.65%
2021-03-31	-8.07%
2020-12-31	-2.92%
2020-09-27	2.12%
2020-06-28	2.30%
2020-03-29	0.56%
2019-12-31	0.14%
2019-09-29	0.41%
2019-06-29	0.29%
2019-03-30	2.02%
2018-12-30	2.90%
2018-09-29	4.52%
2018-06-29	3.74%
2018-03-30	5.44%
2017-12-30	5.23%
2017-09-29	6.54%
2017-06-29	5.15%
2017-03-30	4.57%
2016-12-30	4.32%
2016-09-29	2.17%
2016-06-29	7.80%
2016-03-30	7.83%
2015-12-30	8.68%
2015-09-29	8.58%
2015-06-29	9.54%
2015-03-30	9.59%
2014-12-30	28.55%
2014-09-29	27.17%
2014-06-29	17.40%

DATE

RETURN ON EQUITY (ROE)

2026-06-30

-2.88%

2026-03-31

-2.02%

2025-12-31

-23.89%

2025-09-30

-24.26%

2025-06-30

-22.27%

2025-03-31

-24.22%

2024-12-31

-3.40%

2024-09-30

-4.46%

2024-06-30

-3.31%

2024-03-31

-0.28%

2023-12-31

0.27%

2023-09-30

8.78%

2023-06-30

8.90%

2023-03-31

9.10%

2022-12-31

9.86%

2022-09-30

4.19%

2022-06-30

3.84%

2022-03-31

0.82%

2021-12-31

-6.19%

2021-09-30

-9.09%

2021-06-30

-9.65%

2021-03-31

-8.07%

2020-12-31

-2.92%

2020-09-27

2.12%

2020-06-28

2.30%

2020-03-29

0.56%

2019-12-31

0.14%

2019-09-29

0.41%

2019-06-29

0.29%

2019-03-30

2.02%

2018-12-30

2.90%

2018-09-29

4.52%

2018-06-29

3.74%

2018-03-30

5.44%

2017-12-30

5.23%

2017-09-29

6.54%

2017-06-29

5.15%

2017-03-30

4.57%

2016-12-30

4.32%

2016-09-29

2.17%

2016-06-29

7.80%

2016-03-30

7.83%

2015-12-30

8.68%

2015-09-29

8.58%

2015-06-29

9.54%

2015-03-30

9.59%

2014-12-30

28.55%

2014-09-29

27.17%

2014-06-29

17.40%

Return on Equity (ROE): -2.88%

VTRS Return on Equity (ROE)

VTRS Average Return on Equity (ROE) Chart

VTRS Current vs Average Return on Equity (ROE) Chart

VTRS Return on Equity (ROE) Metrics

VTRS Competitors' Return on Equity (ROE)

Return Analysis

Return on Equity (ROE) Formula & Definition

Return on Equity (ROE) FAQ

VTRS Return on Equity (ROE) History

Related Metrics